Previous 10 | Next 10 |
2024-05-31 15:00:07 ET Luca Issi from RBC Capital issued a price target of $160.00 for MRNA on 2024-05-31 13:55:00. The adjusted price target was set to $160.00. At the time of the announcement, MRNA was trading at $141.83. The overall price target consensus is at $158.4...
2024-05-31 11:11:00 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Third human bird flu case found in U.S. ...
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mR...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
2024-05-28 12:00:24 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued New COVID FLiRT variants spike as FDA del...
2024-05-26 06:50:00 ET The past two-and-a-half years have been rough for Moderna (NASDAQ: MRNA) . Though the biotech was highly successful in the COVID-19 vaccine market, investors rightly expecting this niche to shrink started selling off the stock in early 2022. The vaccine maker'...
2024-05-24 15:00:53 ET More on the markets S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards Stocks have more room to run - Invesco's Kristina Hooper Big bear Mike Wilson changes tune a...
Shares of Moderna, Inc. (NASDAQ: MRNA) traded at a new 52-week high today and are currently trading at $165.24. So far today, approximately 1.47M shares have been exchanged, as compared to an average 30-day volume of 4.17M shares. Moderna, Inc., a biotechnology company, discovers, develops, a...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...